Standard Competitors
| LAB Stock | USD 1.05 0.05 4.55% |
Standard Biotools vs Bioventus Correlation
Excellent diversification
The correlation between Standard Biotools and BVS is -0.58 (i.e., Excellent diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Standard Biotools and BVS in the same portfolio, assuming nothing else is changed.
Moving together with Standard Stock
Moving against Standard Stock
As of March 3, 2026, Return On Tangible Assets is expected to decline to -0.14. In addition to that, Return On Capital Employed is expected to decline to -0.21. At present, Standard Biotools' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 131.3 M, whereas Return On Tangible Assets are forecasted to decline to (0.14).Standard Biotools Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Standard Biotools and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Standard and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Standard Biotools does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Standard Stock performing well and Standard Biotools Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Standard Biotools' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| VREX | 1.32 | 0.18 | 0.12 | 0.21 | 1.47 | 3.53 | 9.48 | |||
| CBLL | 2.22 | 0.16 | 0.06 | 0.24 | 2.43 | 5.06 | 14.49 | |||
| CGEM | 3.96 | 0.82 | 0.21 | 0.66 | 3.48 | 8.36 | 45.76 | |||
| AVNS | 1.75 | 0.17 | 0.07 | 0.22 | 2.22 | 4.13 | 15.78 | |||
| SY | 2.87 | (0.05) | 0.00 | 0.04 | 3.86 | 5.54 | 21.31 | |||
| ADCT | 3.25 | (0.03) | (0.01) | 0.03 | 4.17 | 8.03 | 22.62 | |||
| TMCI | 3.20 | (0.95) | 0.00 | (0.34) | 0.00 | 6.35 | 22.21 | |||
| KIDS | 1.97 | 0.05 | 0.02 | 0.13 | 2.23 | 5.64 | 16.89 | |||
| CTKB | 2.00 | (0.49) | 0.00 | (0.28) | 0.00 | 3.95 | 15.14 | |||
| BVS | 1.56 | 0.21 | 0.08 | 0.35 | 1.98 | 4.31 | 12.08 |
Cross Equities Net Income Analysis
Compare Standard Biotools and related stocks such as Varex Imaging Corp, CeriBell, and Cullinan Oncology LLC Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VREX | 109.6 M | 109.6 M | 109.6 M | 110.1 M | 80 M | 68.5 M | 51.6 M | 27.5 M | 15.5 M | (57.9 M) | 17.4 M | 30.3 M | 48.2 M | (47.7 M) | (70.3 M) | (63.3 M) | (60.1 M) |
| CBLL | (37.2 M) | (37.2 M) | (37.2 M) | (37.2 M) | (37.2 M) | (37.2 M) | (37.2 M) | (37.2 M) | (37.2 M) | (37.2 M) | (37.2 M) | (37.2 M) | (37.2 M) | (29.5 M) | (40.5 M) | (53.4 M) | (56.1 M) |
| CGEM | (704.7 K) | (704.7 K) | (704.7 K) | (704.7 K) | (130.5 K) | (109.5 K) | (316.7 K) | (14.2 M) | (14.2 M) | (20 M) | (50.8 M) | (65 M) | 111.2 M | (153.2 M) | (167.4 M) | (150.6 M) | (143.1 M) |
| AVNS | 142.4 M | 142.4 M | 152.6 M | 154.6 M | 27.1 M | (426.3 M) | 39.8 M | 79.3 M | 57.5 M | (45.9 M) | (27.2 M) | 6.3 M | 50.5 M | (61.8 M) | (392.1 M) | (67.9 M) | (64.5 M) |
| SY | (81 M) | (81 M) | (81 M) | (81 M) | (81 M) | (81 M) | (81 M) | 17.2 M | 55.1 M | 176.7 M | 5.8 M | (8.4 M) | (65.6 M) | 21.3 M | (589.5 M) | (530.6 M) | (504 M) |
| ADCT | (89.9 M) | (89.9 M) | (89.9 M) | (89.9 M) | (89.9 M) | (89.9 M) | (89.9 M) | (89.9 M) | (123.1 M) | (116.5 M) | (246.3 M) | (230 M) | (157.1 M) | (240.1 M) | (157.8 M) | (142.1 M) | (149.2 M) |
| TMCI | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (3.7 M) | (20.6 M) | (42.8 M) | (49.5 M) | (55.7 M) | (59 M) | (56.1 M) |
| KIDS | (9.5 M) | (9.5 M) | (9.5 M) | (9.5 M) | (9.5 M) | (7.9 M) | (6.6 M) | (8.9 M) | (12 M) | (13.7 M) | (32.9 M) | (16.3 M) | 1.3 M | (21 M) | (37.8 M) | (39.6 M) | (37.7 M) |
| CTKB | (16.8 M) | (16.8 M) | (16.8 M) | (16.8 M) | (16.8 M) | (16.8 M) | (16.8 M) | (16.8 M) | (16.8 M) | (16.8 M) | 19.4 M | 3 M | 2.6 M | (12.1 M) | (6 M) | (66.5 M) | (63.2 M) |
| BVS | (22.4 M) | (22.4 M) | (22.4 M) | (22.4 M) | (12.9 M) | (34.1 M) | (18 M) | (1.6 M) | (12.2 M) | 6.9 M | 16.4 M | 19.4 M | (158.7 M) | (156.2 M) | (33.5 M) | (30.2 M) | (31.7 M) |
Standard Biotools and related stocks such as Varex Imaging Corp, CeriBell, and Cullinan Oncology LLC Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Standard Biotools financial statement analysis. It represents the amount of money remaining after all of Standard Biotools operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Standard Biotools Competitive Analysis
The better you understand Standard Biotools competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Standard Biotools' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Standard Biotools' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Standard Biotools Competition Performance Charts
Five steps to successful analysis of Standard Biotools Competition
Standard Biotools' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Standard Biotools in relation to its competition. Standard Biotools' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Standard Biotools in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Standard Biotools' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Standard Biotools, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Standard Biotools position
In addition to having Standard Biotools in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Junk Bonds Funds Thematic Idea Now
Junk Bonds Funds
Funds or Etfs that invest most of their assets into speculative (junk) bonds or to other fixed income instruments with interest rates 3 to 4 percentage points above government issues. The Junk Bonds Funds theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Junk Bonds Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Standard Biotools Correlation with its peers. For information on how to trade Standard Stock refer to our How to Trade Standard Stock guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Standard Biotools. Expected growth trajectory for Standard significantly influences the price investors are willing to assign. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Standard Biotools assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (0.39) | Revenue Per Share | Quarterly Revenue Growth (0.14) | Return On Assets | Return On Equity |
The market value of Standard Biotools is measured differently than its book value, which is the value of Standard that is recorded on the company's balance sheet. Investors also form their own opinion of Standard Biotools' value that differs from its market value or its book value, called intrinsic value, which is Standard Biotools' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Standard Biotools' market value can be influenced by many factors that don't directly affect Standard Biotools' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Standard Biotools' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Standard Biotools represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Standard Biotools' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.